have been associated with nicotine dependence [27,30] and with abstinence [51]. Recent research using a single RCT has demonstrated that individuals with chr15q25.1 risk haplotypes [22,23] exhibit statistically significantly reduced abstinence when randomized to PLA versus no effect on abstinence when randomized to active pharmacotherapy [52], encouraging further exploration of chr15q25.1 associations with response to multiple pharmacotherapies and cessation outcomes in treatment-seeking smokers.
